Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Photodermatol Photoimmunol Photomed ; 40(4): e12978, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38845020

RESUMO

BACKGROUND: Infections are complications in the wound healing process, and their treatment can lead to antibiotic overuse and bacterial resistance. Antimicrobial photodynamic therapy (aPDT) is used to treat infectious diseases caused by fungi, viruses, or bacteria. Methylene blue (MB) and its derivatives are commonly used dyes in antimicrobial photodynamic therapy (aPDT-MB). METHODS: This study is a PRISMA systematic review of animal models used to discuss the usefulness and therapeutic parameters of aPDT-MB or its derivatives for treating infected skin wounds. RESULTS: After an extensive literature review, 13 controlled trials totaling 261 animals were selected to evaluate skin infection by leishmaniasis and cutaneous bacterial and fungal infections. All studies found results favoring the use of aPDT-MB. Great variability in parameters was found for radiant exposure from 12 to 360 J/cm2, MB diluted in saline solution or distilled water, irradiation time from 40 to 3600 s, irradiance most commonly at a maximum of 100 mW/cm2, and wavelength used mainly in the 630-670 nm range. CONCLUSION: MB is a safe and promising agent used as a photosensitizer in aPDT for skin-infected lesions. There is great variability in the parameters found. Comparisons concerning concentration, irradiation time, and light intensity need to be performed.


Assuntos
Azul de Metileno , Fotoquimioterapia , Fármacos Fotossensibilizantes , Animais , Modelos Animais de Doenças , Azul de Metileno/farmacologia , Azul de Metileno/uso terapêutico , Fotoquimioterapia/métodos , Fármacos Fotossensibilizantes/farmacologia , Fármacos Fotossensibilizantes/uso terapêutico
2.
Odonto (Säo Bernardo do Campo) ; 7(16): 42-5, jul. 1999.
Artigo em Português | LILACS, BBO - Odontologia | ID: lil-262523

RESUMO

O ameloblastoma é um tumor benigno, cujo tratamento cirúrgico normalmente leva a grandes perdas de estruturas, mas oferece cura clínica. O tratamento pós-cirúrgico é essencialmente protético, e a reabilitaçäo do paciente visa reparar a mutilaçäo cirúrgica, que ocorre no esqueleto fixo da face e nas estruturas adjacentes, permitindo que o paciente tenha suas funçöes, a estética e o fator psicológico restabelecidos


Assuntos
Ameloblastoma/terapia , Doenças Maxilares
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...